Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 18.4%
Gross margin was 18.4% in Q1 FY2026, down 56.7 pp from a year earlier. On a trailing-twelve-month basis it was 75.0%, down 5.9 pp year over year. Over 3 fiscal years it widened by 24.2 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 81.5%
- Year-over-year change
- -1.5pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.5% | -1.5pp |
| FY2024 | 2024-12-31 | 83.0% | +4.5pp |
| FY2023 | 2023-12-31 | 78.5% | +21.3pp |
| FY2022 | 2022-12-31 | 57.3% | -1.4pp |
| FY2021 | 2021-12-31 | 58.7% | — |
Gross Margin vs competitors
How DNA compares with its peers on the latest reported figures
- DNA's LTM Mar 2026 gross margin of 75.0% is the 4th highest of the 7 companies compared; the peer median is 72.4%.
- Its year-over-year change of -5.9 pp is the 6th highest of 7, against a peer median of +14.4 pp.
- Over three fiscal years its change of +24.2 pp compares with a peer median of -2.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 275.2% | +2604.6 pp | +21.4 pp | |
| LTM Mar 2026 | 97.4% | -2.2 pp | -2.0 pp | |
| LTM Mar 2026 | 91.6% | +64.6 pp | -6.0 pp | |
| LTM Mar 2026 | 75.0% | -5.9 pp | +24.2 pp | |
| LTM Sep 2026 | 53.2% | +23.4 pp | — | |
| LTM Jun 2026 | 34.6% | +5.5 pp | -62.9 pp | |
| LTM Mar 2026 | 29.5% | -17.1 pp | +28.5 pp | |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding DNA) | 72.4% | +14.4 pp | -2.0 pp | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| Gross Profit | 184.15M | 273.49M | 197.45M | 188.49M | 138.63M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research & Development | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Selling, General & Admin | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Operating Expenses | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| Depreciation & Amortization | 29.08M | 61.63M | 71.55M | 63.02M | 58.99M |
| EBITDA | (1.81B) | (2.06B) | (821.29M) | (484.39M) | (254.61M) |
| EBITDA Margin | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| Operating Income | (1.83B) | (2.21B) | (864.41M) | (559.76M) | (315.28M) |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Income | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.37M | 106K | 93K | 94K | 0 |
| Other Income / Expenses | (9.66M) | 87.55M | (28.53M) | 12.25M | 1.68M |
| Income Before Tax | (1.84B) | (2.12B) | (892.94M) | (547.51M) | (313.6M) |
| Pre-Tax Margin | -585.7% | -444.1% | -355.1% | -241.1% | -184.3% |
| Income Tax Expense | (1.48M) | (15.03M) | (71K) | (479K) | (837K) |
| Net Income | (1.83B) | (2.1B) | (892.87M) | (547.03M) | (312.76M) |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Basic) | (53.83) | (50.15) | (18.37) | (10.54) | (5.64) |
| EPS (Diluted) | (55.53) | (50.20) | (18.40) | (10.54) | (5.64) |
| Weighted Avg Shares | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Weighted Avg Shares (Diluted) | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.